- Dr Paul Ashton, President & Ceo, pSivida
- Professor Gregor Cevc, Chief Executive Officer, IDEA AG
- Alan Johnson, Partner, Bristows
- Dr Thomas Keller, Director - Biophysical Sensors & Nanomaterials PCD, GlaxoSAE Media GroupthKline
- Dr Vitaliy Khutoryanskiy, Lecturer in Pharmaceutics, University of Reading
- Dr Roger Kravtzoff, Director of Clinical and Preclinical Development, Flamel Technologies
- Dr Andrew Lewis, Operations Director, Critical Pharmaceuticals
- Dr Mario Maio, Head of Formulation and Process Development, Merck
- Dr Hassan Mohammad, Principal Scientist, Mundipharma International
- Gerben Moolhuizen, Chief Business Officer, OctoPlus
- Dr Joseph P. Reo, Research Fellow, Schering Plough Consumer Healthcare
- Dr Andreas Schatzlein, Reader in Cancer Pharmacology, The School of Pharmacy, University of London
- Dr Peter Scholes, VP Pharmaceutical Sciences, Quotient Clinical Ltd
- Professor Howard Stevens, Emeritus Professor of Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
- Dr Jens Uhlemann, Head of Product Design & Nanotechnology, Bayer Technology Services
- Professor Ian Wilding, Professor, Institute of Pharmaceutical Sciences, Nottingham University & President, Ian Wilding Associates Limited
- Dr Katie Amssoms, Senior Scientist, Tibotec
- Dr Gurjit Bajwa, Principal Scientist, Pfizer
|
|